Spencer-Green et al. IA TLC599 (liposomal dexamethasone) in knee OA. Injection baseline and week 24. Both assoc improved symptoms. As always, look at that placebo injection response! Abstr#L19 #ACR23 @RheumNow https://t.co/oYtkYVboKu https://t.co/RweDRdSieQ

L17 @ #ACR23 New therapy on horizon for cutaneous LE (CLE)? ⭐️AFIMETORAN ➡️ TLR7/8 inhibitor ➡️1st-in-class orally bioavailable, potent ⭐️Phase Ib trial ➡️Criteria: 👉18-65 yo SLE vs biopsy proven CLE 👉CLE Dz Area & Severity Index (CLASI-A) at least 6 👉ANA… https://t.co/HPqw4d0AHl https://t.co/5u9aEvzdMb

#ACR23 Late-Breaking Abstr#L19 IA steroid can help osteoarthritis knee pain but effect & duration are variable. Phase 3 RCT: improvement in ADP & WOMAC pain favouring TLC5999 (liposomal modification of DEX) vs PBO at all timepoints inc. after repeated injection @RheumNow #ACRBest https://t.co/xUhoFHPExr

Would intraarticular steroids for knee OA be better with a sustained release formulation? ph3, TLL599 (liposomal delivery dexamethasone) vs normal dex vs placebo some gains over normal dex well tolerated New options always welcome in OA! @ProfDavidHunter #ACR23 L19 @RheumNow https://t.co/TUrhppHMiD

L20 #ACR23 @RheumNow Telitacept - Recomb Fusion targets BlyS, APRIL in RA w inadeq MTX response ACR 20 60% v 27% PBO (p<0.001), ACR 50 21% v 6% PBO (p<0.001) DAS28-ESR <3.2 15% v 5%, reduct -1.6 v -1.0 Better PROs, less jt damage prog at w24 Safety SAE 6.4 v 6.7%, no ifn signal https://t.co/PsA6AxUHVW

Sustained relief for knee OA TLC599 - liposomal formulation of dexamethasone sodium phosphate Single injection provided relief for 24 weeks, repeat injection with benefit up to wk 52 @RheumNow #ACR23 Abs#L19 #ACRBest https://t.co/BNGb3nHw8C

#ACR23 Late-Breaking Abstr#L20 Phase 3 RCT in China: Telitacicept (BAFF-APRIL-i) in MTX-IR #RA met ACR20 response vs PBO. +ve: less radiographic damage -ve: lower rate ACR50 (21%), homogenous population, no H2H active comparator Unclear its place in current Mx @RheumNow https://t.co/SAc4B1aRD1

Telitacicept (BlyS/APRIL inhibitor) ph3 in RA wholly in China, after SLE approval there (SLE trial now w global sites) Efficacy okay, no better than other b/tsDMARDs What's the hook here, in a crowded RA market incl biosimilars? Safety does look good though #ACR23 L20 @RheumNow https://t.co/UzQ0f18E2A

ICYMI Interesting study by Dr LWGarcia et al: 👉IFN-a serum levels predicted failure to respond to tx 2 years after a flare in pts w/ LN 👉Pts w/⬆️BL IFN-a levels had greater risk of having 2 or more subsequent flares #ACR23 ABST2297 @RheumNow @ZahiTouma https://t.co/WJZnNUPUbT

Interesting late breaker! Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression No difference in safety profile compared to placebo @RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt

Telitacicept (BlyS/APRIL inhibitor) in MTX-IR RA. Phase 3 RCT. 479 patients. ACR20 60.0% vs 26.9%. ACR50 21.4% vs. 5.9%. Radiographic benefit also. Safety looks ok. Abstr#L20 #ACR23 #ACRbest @RheumNow https://t.co/qcinGeRX2d https://t.co/SIKKW7xhwV